Handouts.pdf
- 2. Geraldine Hill, Uppsala Monitoring Centre 2 PV Methods: which one? Spontaneous Reporting Cohort Event Monitoring Targeted Reporting EHR Mining Intensified ADR Reporting Record Linkage
- 3. Geraldine Hill, Uppsala Monitoring Centre 3 What is your objective? • To establish a functional reporting system to monitor the safety of all medicines • To learn more about the safety profile of new medicines in the early post-marketing phase • To learn more about the ADR profile of a specific medicine(s) in your population • To estimate the incidence of a known ADR to a specific medicine in your population • To gather more information on the safety profile of a new chemical entity in early post-marketing phase • To make use of existing electronic health records and registries to support pharmacovigilance activitites
- 4. Geraldine Hill, Uppsala Monitoring Centre 4 PV Methods Spectrum Spontaneous Reporting Intensified ADR Reporting Targeted Reporting Cohort Event Monitoring EHR Mining
- 5. Geraldine Hill, Uppsala Monitoring Centre 5 Spontaneous Reporting Objective: a functional ADR reporting system to monitor the safety of all medicines • Voluntary submission of ICSRs by health professionals, pharmaceutical manufacturers (and patients) to the national pharmacovigilance centre • Requires two initial steps: A patient or health professional 1. suspects that an undesirable medical event may have been caused by exposure to a medicine 2. reports the suspicion to the national pharmacovigilance centre
- 6. Geraldine Hill, Uppsala Monitoring Centre 6 Spontaneous Reporting: what to report? Developing Pharmacovigilance System • All suspected ADRs – Encourage a culture of ADR reporting – Build PV capacity – Develop a profile of ADRs experienced with locally used medicines • If in doubt, report!
- 7. Geraldine Hill, Uppsala Monitoring Centre 7 Spontaneous Reporting: what to report? Established Pharmacovigilance System • May wish to restrict what is reported e.g. MHRA and EMA countries limit reporting to: – All suspected ADRs for new medicines – All suspected ADRs occurring in children, even if a medicine has been used off-label – All serious* suspected ADRs for established vaccines and medicines, including unlicensed medicines, herbal remedies and medicines used off-label. * fatal, life-threatening, causing permanent disability, prolonging hospitalisation or medically significant • If in doubt, report!
- 8. Geraldine Hill, Uppsala Monitoring Centre 8 Spontaneous Reporting Pros Cons Covers the whole population Includes all medicines Continual monitoring throughout life- cycle of a medicine Detects signals of new, rare or serious ADRs Most commonly used method Easiest method to establish Relatively inexpensive Least labour intensive Inherent under-reporting Captures only suspected ADRs Reporting bias e.g. Seriousness, severity New medicine Advertising of product Publicity of specific ADR Denominator unknown Difficult to detect ‒ delayed ADRs & ‒ ADRs with high background incidence
- 9. Geraldine Hill, Uppsala Monitoring Centre 9 Intensified ADR Reporting Objective: to enhance ADR reporting of specific medicines in early post-marketing phase • Extension of Spontaneous Reporting Programme Black Triangle Scheme This medicinal product is subject to additional monitoring • System in place in UK for many years; to be introduced in EU from Autumn 2013. • List of medicines ’under additional reporting’ reviewed monthly http://www.mhra.gov.uk http://www.ema.europa.eu
- 10. Geraldine Hill, Uppsala Monitoring Centre 10 Intensified ADR Reporting • Medicines ’under additional monitoring’ include: – Medicines containing a new active substance – Biological medicines – Medicines given conditional approval or approved under exceptional circumstances – Medicines that require additional studies (e.g. More data on long term use or on a rare side effect seen in clinical trials)
- 11. Geraldine Hill, Uppsala Monitoring Centre 11 Targeted Spontaneous Reporting Objective: • To learn more about the ADR profile of a specific medicine(s) in your population or • To estimate the incidence of a known ADR to a specific medicine in your population
- 12. Geraldine Hill, Uppsala Monitoring Centre 12 Targeted Reporting Specific ADR All ADRs Specific Clinics Specific Medicine(s) Specific Population
- 13. Geraldine Hill, Uppsala Monitoring Centre 13 Targeted Reporting TSR of suspected ADRs to ARVs, AMPATH, Eldoret, Kenya • AMPATH (Academic Model Providing Access to Healthcare) – Partnership between Moi University School of Medicine, Moi Teaching and Referral Hospital and a consortium of US medical schools led by Indiana University. – Treats over 125,000 HIV-positive patients at 53 sites in and around Eldoret, Western Kenya. • Focusing on treatment-threatening ADRs (change or discontinuation of treatment) • Investigating different methods of collecting ADR data, including: – Spontaneous reporting of suspected ADR by clinician – Spontaneous reporting of suspected ADR by pharmacist – Interview by pharmacist of random sample of patients – Interview by peer of random sample of patients – Pharmacy dispensing data (to assess under-reporting)
- 14. Geraldine Hill, Uppsala Monitoring Centre 14 TSR pilot project in Uganda: • Monitoring Medicines Project • Collaboration between National Pharmacovigilance Centre and AIDS Control Programme • Objectives include: • To monitor renal toxicities related to use of Tenofovir (TDF)-based regimens in adults • To monitor ADRs related to use of Zidovudine (AZT) for PMTCT • To enhance pharmacovigilance in AIDS control programme • Screening for renal toxicity follows routine practice • ADRs are reported ‘spontaneously’ if observed Targeted Reporting
- 15. Geraldine Hill, Uppsala Monitoring Centre 15 Objective: To gather more information on the safety profile of a new chemical entity in early post-marketing phase • New class of medicine • Medicine related to class of medicine that has previously caused problems • Potentially significant adverse event observed during pre- or post-marketing surveillance (SR) Cohort Event Monitoring (CEM)
- 16. Geraldine Hill, Uppsala Monitoring Centre 16 Decision to monitor influenced by: • A need for more safety data (in general or in relation to a particular clinical use) • Expected long-term use • Expected widespread use • Where increase in risk/benefit ratio would be unacceptable (e.g. ‘life-style drugs’) • One of several treatment options for a disease, where other treatment options are considered safe and effective.
- 17. Geraldine Hill, Uppsala Monitoring Centre 17 Cohort Event Monitoring (CEM) A prospective, longitudinal, observational, cohort study of adverse events associated with one or more monitored medicines
- 18. Geraldine Hill, Uppsala Monitoring Centre 18 Cohort Event Monitoring Prospective ‘Real-time’ monitoring Longitudinal Over a period of time (Inceptional) From start of treatment Observational Does not interfere with patient management Cohort Defined group of patients Adverse events ‘Any new clinical experience (favourable or unfavourable) that is worthy of a record in the patient’s file, regardless of its severity and without judgement on its causality’ Monitored medicine Specific medicine(s)
- 19. Geraldine Hill, Uppsala Monitoring Centre 19 Cohort Event Monitoring • Records ALL CLINICAL EVENTS not just suspected adverse reactions • A time-limited programme to complement other PV activities; not intended to replace spontaneous reporting
- 20. Geraldine Hill, Uppsala Monitoring Centre 20 Patient Hospitals & Clinics Health Care Provider Medical Assessor Event Recording Data Collation Signal? Signal Evaluation Communication Expert Advisory Committee Pharmacovigilance Centre Uppsala Monitoring Centre Stakeholders Data Entry Cohort Event Monitoring Data Entry Staff Event Causality Assessment
- 21. Geraldine Hill, Uppsala Monitoring Centre 21 CEM enables us to: • Characterise known reactions • Detect signals of unrecognised reactions • Identify interactions with other medicines and TCAMs • Detect inefficacy of medicine • Assess safety in pregnancy & lactation • Measure risk (including comparative risk) • Identify risk factors for ADRs
- 22. Geraldine Hill, Uppsala Monitoring Centre 22 CEM Programmes (CemFlow) HIV Belarus RCETH CEM for ARV medicines in Republic of Belarus Malaria Ghana FDA (Ghana) CEM Malaria (WHO) CEM Malaria (AMFm) INESS INESS International CEM Ghana Kenya PPB CEM-AL Kenya Nigeria NAFDAC CEM for Malaria (Pilot) CEM for Malaria (Scale-up) Tanzania TFDA TANCEM (ALu) TANCEM – DHA/PPQ INESS INESS International CEM Tanzania Zimbabwe Medicines Control Authority of Zimbabwe ZimCemFlow ACT
- 23. Geraldine Hill, Uppsala Monitoring Centre 23 Monitored Antimarlarial Medicines Ghana CEM Malaria (WHO) All antimalarials CEM Malaria (AMFm) AL, AsAq INESS International CEM Ghana AqAr Kenya CEM-AL Kenya AL Nigeria CEM for Malaria (Pilot) AL, AsAq CEM for Malaria (Scale-up) AL, AsAq Tanzania TANCEM (ALu) AL TANCEM –DHA/PPQ DP INESS International CEM Tanzania AL Zimbabwe ZimCemFlow ACT AL AL artemether+lumefantrin AqAm amodiaquine+artemether AsAq artesunate+amodiaquine DP dihydroartemisinin+piperaquine
- 24. Geraldine Hill, Uppsala Monitoring Centre 24 Cohort Event Monitoring Pros Cons Early detection of signals of unsuspected ADRs Denominator information allows incidence rates of ADRs to be calculated Near complete profile of AEs/ADRs for medicine of interest Assessment of risk; identification of risk factors; between drug comparisons Pregnancy outcomes Deaths recorded More labour intensive than SR or TSR More costly Much data collected most of which represents ‘background noise’ New to health professionals and PV Centres Training required LTFU may be substantial and needs to be actively managed
- 25. Geraldine Hill, Uppsala Monitoring Centre 25 Workload considerations Example: Antimalarial Monitoring Target size of cohort: 3000 patients (3300 patients to allow for 10% LTFU); 10 sites (330 patients per site) 5 patients per week, 2 visits over 1 week 660 data collection forms (DCFs) from 1 monitoring site 6600 DCFs in total 0 2 4 6 8 10 12 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 Data collection forms Week
- 26. Geraldine Hill, Uppsala Monitoring Centre 26 Workload considerations Example: ARV Monitoring Target size of cohort: 3000 patients (3300 patients to allow for 10% LTFU); 10 sites (330 patients per site) 5 patients per week, 14 visits over 12 months (wk 0, 2, 6, 10... (monthly)...50) 4620 reports from 1 monitoring site 46200 reports in total 70
- 27. Geraldine Hill, Uppsala Monitoring Centre 27 Electronic Health Record Mining Objective: make use of existing health records to supplement pharmacovigilance activities • Electronic Health Records - a potentially rich source of ADR data • Mining of the THIN data-base is currently being evaluated • More to come on this later...!
- 28. Geraldine Hill, Uppsala Monitoring Centre 28 PV Methods Spectrum Spontaneous Reporting Intensified ADR Reporting EHR Mining Cohort Event Monitoring Targeted Reporting Denominator unknown Suspected ADRs All medicines Denominator unknown Suspected ADRs Specific medicines Denominator known Suspected ADRs Cohort specific medicines Denominator known All Events Cohort specific medicines Denominator known All Events All medicines WHO Programme for International Drug Monitoring CEM of new antimalarials (ACTs) PROTECT 3.10 Mining of THIN database TSR of Tenofivir in Uganda; UK/EU Black Triangle Scheme Denominator known Specific ADRs Cohort specific medicines AMPATH Kenya ARVs Essential minimum reporting Early post- marketing phase of new drugs Profile of ADRs for a specific medicine in a specific popn Incidence of a known ADR in a specific population Post-marketing surveillance of a new chemical entity Making use of existing records to enhance PV
- 29. Geraldine Hill, Uppsala Monitoring Centre 29 Comparing the methods Method Medicines Population Reports Spontaneous Reporting All medicines, life-cycle of product All exposed individuals but denominator unknown All ADRs Intensified ADR Reporting Specific medicines All exposed individuals but denominator unknown All ADRs Targeted Reporting Specific medicines Defined cohort Specific ADRs All ADRs Cohort Event Monitoring Specific medicines Defined cohort All Events EHR Mining All medicines Defined cohort All Events
- 30. Geraldine Hill, Uppsala Monitoring Centre 30 Uppsala Monitoring Centre Box 1051 SE-751 40 Uppsala, Sweden Visiting address: Bredgränd 7, Uppsala tel +46 18 65 60 60 fax +46 18 65 60 88 website www.who-umc.org Tack så mycket